By 
Advances in fertility medicine have expanded the level of detail available during embryo assessment. One of the most widely used tools in modern IVF practice is NGS testing Bangkok, which applies next generation sequencing to analyze embryo chromosomal status before transfer. This approach allows clinicians to evaluate whether an embryo has the correct number of chromosomes, which is a major factor in implantation success and ongoing pregnancy.
Chromosomal abnormalities are common in human embryos, particularly as maternal age increases. These abnormalities may prevent implantation or result in early miscarriage. By examining the genetic material at a detailed level, sequencing based testing provides additional information to guide embryo selection decisions during treatment planning.
How Next Generation Sequencing Works in IVF
The testing process typically occurs at the blastocyst stage, around five to six days after fertilization. At this stage, the embryo has developed into a structure with an inner cell mass and an outer layer called the trophectoderm. A small number of cells are carefully removed from the outer layer, which later forms part of the placenta. This biopsy is performed using precise laboratory techniques designed to minimize disruption to embryo development.
The sampled cells are then analyzed in a specialized laboratory using sequencing technology capable of detecting whole chromosome gains or losses, as well as certain segmental abnormalities. While the analysis is being completed, the embryo is cryopreserved. Once results are available, clinicians can identify which embryos show a normal chromosomal complement and which do not.
The goal of testing is to support informed selection. Transferring an embryo with the correct number of chromosomes may reduce the likelihood of implantation failure or miscarriage related to chromosomal imbalance. It does not guarantee pregnancy, but it addresses one significant biological variable.
What the Results Mean for Patients
Results are usually categorized as chromosomally normal, abnormal, or in some cases mosaic, meaning a mixture of normal and abnormal cells was detected in the sample. The interpretation of mosaic results requires careful clinical judgment and discussion with the patient.
For individuals of advanced maternal age or those with repeated IVF failure, sequencing can provide additional clarity during decision making. Instead of selecting embryos based solely on appearance under the microscope, clinicians can incorporate chromosomal data into the selection process.
It is important to recognize the limitations of testing. Not all causes of implantation failure are chromosomal. Uterine health, hormonal environment, and general reproductive factors also influence outcomes. Sequencing provides valuable information about chromosomal status, but it does not evaluate every possible genetic or developmental condition.
Counseling remains an essential part of the process. Patients should understand what the test can and cannot detect, as well as how results may influence treatment planning. Clear explanation reduces misunderstanding and supports realistic expectations.
Next generation sequencing has become integrated into many IVF programs because it enhances the level of information available at a critical decision point. By examining embryo chromosomal structure in greater detail, clinicians can make more data informed choices during embryo transfer planning while continuing to monitor other factors that influence pregnancy success.
Comments